{"id":"NCT01197417","sponsor":"Medical College of Wisconsin","briefTitle":"Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis","officialTitle":"Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-12","primaryCompletion":"2014-03","completion":"2014-03","firstPosted":"2010-09-09","resultsPosted":"2015-09-07","lastUpdate":"2016-01-27"},"enrollment":208,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Sickle Cell Disease"],"interventions":[{"type":"DRUG","name":"Intravenous Magnesium Sulfate","otherNames":[]},{"type":"DRUG","name":"Normal Saline Placebo","otherNames":[]}],"arms":[{"label":"Magnesium group","type":"EXPERIMENTAL"},{"label":"Placebo group","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of intravenous magnesium in shortening the duration of a pain crisis and to determine the health-related quality of life and short term outcomes of children treated with intravenous magnesium during an acute pain crisis.","primaryOutcome":{"measure":"Hospital Length of Stay (Hours)","timeFrame":"From the time of the start of first study med infusion until hospital discharge or 12 hours after the last IV opioid, whichever occurs first, up to 10 days post enrollment","effectByArm":[{"arm":"Magnesium Group","deltaMin":56,"sd":null},{"arm":"Placebo Group","deltaMin":47,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.24"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":["26232172","28606098","24443249"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":101},"commonTop":["Fever","Nausea","Headache","Oxygen saturation decreased","Itching"]}}